伊克力西斯 EXEL 深 沪
已收盘 07-02 16:00:00 美东时间
55.85
+1.890
+3.50%
华盛通- 最 高56.21
- 今 开54.43
- 成交量 236.41万股
- 最 低 54.10
- 昨 收 53.96
- 总市值 140.38亿
- 52周最高 56.21
- 市盈率 静 20.12
- 换手率 0.94%
- 52周最低 33.755
- 委 比 -5.15%
- 总股本 2.51亿
- 历史最高 56.21
- 量 比 0.73
- 振 幅 3.91%
- 历史最低 1.26
- 每 手 1
- 风险率 4.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多HC Wainwright & Co. Reiterates Buy on Exelixis, Maintains $56 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Exelixis (NASDAQ:EXEL) with a Buy and maintains $56 price target.
07-02 18:49
美股大行评级 | 潜在涨幅135.66%！Ocular Therapeutix获Chardan Capital升目标价至23美元，维持"买入"评级
今日重点评级关注：Chardan Capital：维持Ocular Therapeutix"买入"评级，目标价从21美元升至23美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从30美元升至40美元
06-26 17:42
This PVH Analyst Turns Bearish; Here Are Top 3 Downgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. B of A Securities analyst Heather Balsky downgraded PVH Corp (NYSE:PVH) from Neutral to Underperf...
06-25 22:17
美股大行评级 | 瑞银上调超微公司目标价从455美元升至670美元，上调ARM目标价从260美元升至470美元；美银证券上调台积电目标价从490美元升至590美元
今日重点评级关注：Jones Trading：维持Definium Therapeutics"买入"评级，目标价从61美元升至74美元；韦德布什：维持Cerebras Systems"跑赢大市"评级，目标价从270美元升至280美元
06-25 11:32
Citizens Maintains Market Outperform on Exelixis, Raises Price Target to $55
Citizens analyst Silvan Turkcan maintains Exelixis (NASDAQ:EXEL) with a Market Outperform and raises the price target from $50 to $55.
06-24 21:00
Exelixis Reports Final STELLAR‑303 Analysis; Zanzalintinib In Combination With Tecentriq Showed Non‑Significant OS Trend Favoring Combo In Non‑Liver Metastases mCRC
Exelixis, Inc. (NASDAQ:EXEL) today announced results from the final analysis of the dual primary endpoint of overall survival (OS) in the subset of patients without active liver metastases (non-liver metastases, NLM) in the phase 3 STELLAR-303 pivotal trial evaluating zanzalintinib in combination wi...
06-22 20:13
美股盘后 | Paramount Skydance涨2.96%，Alamos Gold Inc.涨2.27%
Paramount Skydance涨2.96%；Alamos Gold Inc.涨2.27%；美国空气化工产品涨2.27%
06-13 06:10
Exelixis Enters Clinical Development Collaboration With Merck For Its KEYTRUDA QLEX Injection In Combination With Zanzalintinib In The STELLAR-316 Phase 3 Trial
STELLAR-316 is a planned phase 3 pivotal trial in patients with resected stage II/III colorectal cancer (CRC). Under the terms of the clinical development collaboration with Merck, Exelixis is sponsoring the STELLAR-316
05-19 20:10
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
